Summary
Traditional therapy of acute myelogenous leukemia has not cured more than 10% of patients and, of acute lymphoblastic leukemia not more than 30% of adults. In part, this is due to the lack of agents effective enough to induce remissions of such quality that cure is possible. The introduction of mitoxantrone and its use in high dose with high-dose cytarabine for induction therapy, raises the possibility of an increased cure rate of acute myelogenous leukemia and acute lymphoblastic leukemia.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Arlin ZA, Feldman E, Kempin S, Ahmed T, Mittelman A, Savona S, ascensao J, Baskind P, Sullivan P, Fuhr HG, Mertelsmann R, Amsacrine with high-dose cytarabine is highly effective therapy for refractory and relapsed acute lymphoblastic leukemia in adults. Blood 72: 433, 1988
Arlin ZA, Case DC Jr, Moore J, Wiernik P, Saletan S, Desai P, Sia L, Cartwright K and the Lederle Cooperative Group, Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adults with acute nonlymphocytic leukemia (ANLL). Leukemia 4: 177, 1990
Arlin ZA, Feldman EJ, Finger LR, Ahmed T, Mittelman A, Cook P, Puccio C, Baskind P, Arnold P, Razis ED, Decter J, Chun HG. Short-course high-dose mitoxantrone with high-dose cytarabine is effective therapy for adult lymphoblastic leukemia. Leukemia 5: 712, 1991
Arlin ZA, Feldman EJ, Finger L, Ahmed T, Mittelman A, Puccio C, Cook P, Chun HG, “Quality” remissions: a new target of induction therapy in acute leukemia and the next step in developing curative treatment. Semin Hematol 28: 44, 1991
Arlin Z, Ahmed T, Mittelman A, Puccio C, Cook P, Chun H, Helson L, Improved quality of remission in acute leukemia: effectiveness of high-dose mitoxantrone, etoposide and cytarabine (abstract), 1992
Barrett AJ, Horowitz MM, Gale RP, Biggs JC, Camitta BM, Dicke KA, Gluckman E, Good RA, Herzig RH, Lee MB, Marmont AM, Masaoka T, Ramsay NKC, Rimm AA, Speck B, Zwaan FE, Bortin MM, Marrow transplantation for acute lymphoblastic leukemia: factors effecting relapse and survival. Blood 74: 862, 1989
Bernard J, Weil M, Boiron M, Jacquillat C, Flandrin G, Gemon MF. Acute promyelocytic leukemia: results of treatment with daunorubicin. Blood 41: 489, 1973
Capizzi RL, Pool M, Cooper MR, Richards F, Stuart JJ, Jackson DD Jr, White DR, Spurr CL, Hopkins JO, Muss HB, Rudnick SA, Wells R, Gabriel D, Ross D, Treatment of poor risk acute leukemia with sequential high-dose ara-c and asparaginase. Blood 63: 694, 1981
Cassileth PA, Begg CB, Silber R, Spiers A, Burkart PT, Scharfman W, Knospe WH, Bennett JM, Mazza JJ, Oken MM, Keller AM, O'Connell MJ, Prolonged unmaintained remission after intensive consolidation therapy in adult acute nonlymphocytic leukemia. Cancer Treat Rep 71: 137, 1987
Chomeinne C, Ballerini P, Balitrand N, Huang ME, Krawice I, Castaigne S, Fenaux P, Tiollias P, Dejean A, Degos I, de The H, The retinoic acid receptor alpha gene is rearranged in retinoic acid-sensitive promyelocytic leukemias. Leukemia 4: 802, 1990
Dahl GV, Rivera GK, Look AT, Husto O, Kalwinski DK, Abromowitch M, Mirro J, Ochs J, Murphy SB, Dodge RK, Pui C, Teniposide plus cytarabine improves outcome in childhood acute lymphoblastic leukemia presenting with a leukocyte count of ≥100×109/l. J Clin Oncol 5: 1015, 1987
Feldman EJ, Arlin ZA, Ahmed T, Mittelman A, Ascensao JL, Puccio CA, Coombe N, Baskind P, Acute promyelocytic leukemia: a 5-year approach with new antileukemic agents and a new approach to preventing fatal hemorrhage. Acta Haematol (Basel) 82: 117, 1989
Feldman E, Biguzzi S, Ahmed T, Mittelman A, Puccio C, Baskind P, Arlin Z, Preliminary experience with short-course high-dose mitoxantrone in combination with high-dose cytarabine in patients with acute leukemia and blastic phase of chronic myelogenous leukemia. Leukemia Lymphoma 3: 209, 1990
Forman SJ, O'Donnell MR, Nademanee AP, Snyder DS, Beirman PJ, Schmidt GM, Fahey JL, Stein AS, Parker PM, Blume KG, Bone marrow transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 70: 587, 1987
Glucksberg H, Chever MA, Farewell VT, Fefer A, Sale GE, Thomas ED, High dose combination chemotherapy for acute nonlymphoblastic leukemia in adults. Cancer 48: 1073, 1981
Herzig RH, Hines JD, Herzig GP, Wolff SN, Cassileth PA, Lazarus HM, Adelstein DJ, Brown RA, Coccia PF, Strandjord S, Mazza JJ, Fay J, Phillips GL, Cerebellar toxicity with highdose cytosine arabinoside. J Clin Oncol 5: 927, 1987
Huang M, Ye Y, Chen S, Chai J, Lu J, Zhoa L, Gu L, Wang Z, Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72: 567, 1988
Preisler HD, Brecher M, Browman G, Early AP, Walker IR, Raza A, Freeman A, The treatment of acute myelocytic leukemia in patients 30 years of age and younger. Am J Hematol 13: 189, 1982
Sauter C, Berchtold W, Fopp M, Gratwohl A, Imbach P, Maurice P, Tschopp L, Fliedner V von, Cavalli F, Acute myelogenous leukaemia: maintenance chemotherapy after early consolidation does not prolong survival. Lancet I: 379, 1984
Tilly H, Castaigne S, Bordessoule D, Casassus P, Le-Prise PY, Tertian G, Desablens B, Henry-Amar FM, Degos L, Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol 8: 272, 1990
Warrell RP Jr, Frankel SR, Miller WH Jr, Scheinberg DA, Itri LM, Hittelman WN, Vyas R, Andreeff M, Tafuri A, Jakubowski A, Gabrilove J, Gordon MS, Dmitrovsky E, Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med 324: 1385, 1991
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Arlin, Z.A., Ahmed, T., Mittelman, A. et al. Higher cure rates in acute leukemia: now more probable with increasingly effective induction therapy. Int J Clin Lab Res 21, 273–277 (1992). https://doi.org/10.1007/BF02591660
Issue Date:
DOI: https://doi.org/10.1007/BF02591660